TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8273796
Drug: Intravenous metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous metronidazole (0.5g tid) and tobramycin (4 mg/kg tid)
Study: 2596737
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 1,500,000 IU streptokinase
Study: 2596737
Drug: Routine anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine anticoagulant therapy (Control)
Study: 1093634
Drug: 0.5 per
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 per cent. idoxuridine ointment (IDU)
Study: 30852657
Drug: Vitamin D-fortified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D-fortified foods (yoghurt, cheese, eggs, crisp bread) providing 20 µg vitamin D3/day
Study: 27773378
Drug: Checklist group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Checklist group (self-administered checklist and paper feedback)
Study: 21066883
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (manipulated acupuncture)
Study: 16902063
Drug: High-fiber, low-fat
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fiber, low-fat diet with daily aerobic exercise for 3 weeks
Study: 6873549
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) at a single weekly dose of 15 mg/kg
Study: 26297203
Drug: Levonorgestrel-releasing 52-mg
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel-releasing 52-mg IUD (LNG-IUD)
Study: 23972263
Drug: Octreotide-LAR (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide-LAR (20 mg intramuscular injections every 28 days for 3 years)
Study: 23972263
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% sodium chloride solution every 28 days for 3 years)
Study: 19233432
Drug: Naftopidil 50
Normalized name: Naftopidil
DrugBank: Naftopidil (DB12092)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Naftopidil 50 mg daily
Study: 16945121
Drug: Tamsulosin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.2 mg once daily
Study: 20707784
Drug: Selegiline transdermal
Normalized name: Selegiline Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline transdermal system (STS)
Study: 10963930
Drug: Individually focused
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually focused cognitive-behavioral treatment
Study: 9011971
Drug: Buffer solution
Normalized name: Buffer Solution, pH 5.00, Reference Standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffer solution
Study: 8214269
Drug: 1% niclosamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% niclosamide lotion applied daily for five months
Study: 8214269
Drug: Placebo lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lotion applied daily for five months
Study: 3323611
Drug: Higher BCKA
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher BCKA content supplement
Study: 3323611
Drug: Lower BCKA
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower BCKA content supplement
Study: 27930553
Drug: 0.9% sodium
Normalized name: LMD with 0.9% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride injection
Study: 20041430
Drug: Ginkgo fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo fresh plant extract tablets
Study: 20041430
Drug: EGb 761
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGb 761 tablets
Study: 11873071
Drug: Subcutaneous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous recombinant interleukin-2 (rIL-2) 4.5 MIU
Study: 11873071
Drug: Subcutaneous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous recombinant interleukin-2 (rIL-2) 7.5 MIU
Study: 11873071
Drug: Subcutaneous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous recombinant interleukin-2 (rIL-2)
Study: 8871752
Drug: Weekly Epoetin
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly Epoetin alfa regimen (600 IU/kg)
Study: 8871752
Drug: Daily Epoetin
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Epoetin alfa regimen (300 IU/kg)
Study: 23152839
Drug: Mipomersen 200
Normalized name: mipomersen 200 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mipomersen 200 mg weekly subcutaneous injections (n = 39)
Study: 20212297
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for chronic diseases
Study: 17352962
Drug: Watermelon juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Watermelon juice (780 g/day)
Study: 17352962
Drug: Watermelon juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Watermelon juice (1560 g/day)
Study: 17352962
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 g watermelon juice)
Study: 11934658
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg estradiol and 1 mg norethisterone acetate
Study: 15730171
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg estradiol and 5 mg norethindrone
Study: 9539585
Drug: Univent tube
Normalized name: Sus scrofa fallopian tube preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Univent tube with bronchial blocker (R-UBB)
Study: 22015616
Drug: Intracoronary bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary bolus administration of abciximab
Study: 22015616
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus administration of abciximab
Study: 16360543
Drug: Gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000 mg/m2, days 1, 8) plus Docetaxel (75 mg/m2, day 1)
Study: 16360543
Drug: Capecitabine (1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (1250 mg/m2, bid days 1-14) plus Docetaxel
Study: 12037739
Drug: Modified intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified intravenous glucose tolerance test (IVGTT)
Study: 12037739
Drug: Insulin sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin sensitivity index (SI)
Study: 12037739
Drug: Insulin secretion
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin secretion (AIR(Glucose))
Study: 1616162
Drug: Atropine (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (0.02 mg/kg)
Study: 20517827
Drug: Placebo (isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (isotonic saline solution)
Study: 8539548
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) 1 g/kg body weight per day over 2 consecutive days
Study: 8539548
Drug: Observation (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation (no specific therapy)
Study: 338254
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 20 mg piribedil tablets
Study: 338254
Drug: 1 x
Normalized name: Black Cohosh 1 X Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 50 mg piribedil in a sustained-release tablet formulation
Study: 31511330
Drug: Fingolimod 0.5
Normalized name: fingolimod 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod 0.5 mg/d
Study: 25419615
Drug: Fingolimod 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod 1.25 mg/d
Study: 25419615
Drug: Other disease-modifying
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other disease-modifying treatments
Study: 25419615
Drug: Corticosteroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid treatment for relapses
Study: 25419615
Drug: Postmarketing setting
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postmarketing setting (Fingolimod 0.5 mg/d)
Study: 19699855
Drug: Nurse-administered disease-management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-administered disease-management intervention combining patient self-management support and provider medication management
Study: 19699855
Drug: Nurse-administered disease-management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-administered disease-management intervention
Study: 31932458
Drug: Sulfonylurea treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylurea treatment
Study: 3553493
Drug: Hydrochlorothiazide (added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (added to treatment)
Study: 27869225
Drug: Noisy galvanic
Normalized name: OCTINOXATE 0.068 g in 1 g TOPICAL LIPSTICK [ESIKA PRO HD COLOR HIGH DEFINITION COLOR SPF 20 (HD BERRY BALCANIC) - RED]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noisy galvanic vestibular stimulation (nGVS) for 30 minutes twice with a 4-hour interval
Study: 19439364
Drug: Modafinil (200-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (200-300 mg/day depending on weight)
Study: 20860068
Drug: Methylphenidate (20-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (20-30 mg/day depending on weight)
Study: 15754390
Drug: Corticosteroids at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids at 60 mg or more daily with or without anti-viral drugs within 10 days after diagnosis (early high-dose group)
Study: 15754390
Drug: Non-early high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-early high-dose group (treated more than 10 days or untreated with corticosteroids)
Study: 6192894
Drug: BCVP (maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCVP (maintenance therapy for responders)
Study: 6192894
Drug: COPA (maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: COPA (maintenance therapy for responders)
Study: 28478716
Drug: Valerian (530
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valerian (530 mg) nightly 1 hour before sleep for 4 weeks
Study: 24722261
Drug: MDCO-2010 (highest
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDCO-2010 (highest dosage groups)
Study: 16965431
Drug: Calcipotriol ointment
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol ointment twice daily
Study: 16965431
Drug: Dithranol cream
Normalized name: Zithranol
DrugBank: Anthralin (DB11157)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dithranol cream once daily
Study: 15788020
Drug: Protein-rich liquid
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-rich liquid supplement (PR; 200 kcal and 20 g protein day(-1))
Study: 15788020
Drug: Protein-rich liquid
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-rich liquid supplement (PR; 200 kcal and 20 g protein day(-1)) + nandrolone decanoate injections (PR/N) 25 mg i.m. every third week
Study: 11849631
Drug: Ortho Evra/Evra
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ortho Evra/Evra transdermal patch (3 consecutive 7-day patches for 21 days with 1 patch-free week)
Study: 11849631
Drug: Ortho Evra/Evra
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ortho Evra/Evra transdermal patch
Study: 10450383
Drug: 0.5 ml
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml carbachol intracamerally (carbachol group)
Study: 10450383
Drug: Balanced salt
Normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balanced salt solution intracamerally (control group)
Study: 6101459
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg synthetic beta-endorphin
Study: 21175373
Drug: Oxybutynin IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin IR 15 mg/day
Study: 19411362
Drug: Clinical vignettes
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical vignettes manipulating expected progress and patient adherence to treatment
Study: 17713338
Drug: Sugar-free gum
Normalized name: Diabetic Multivitamin Sugar-Free Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar-free gum containing 20 mg citric acid and 18.8 mg CPP-ACP
Study: 17713338
Drug: Sugar-free gum
Normalized name: Diabetic Multivitamin Sugar-Free Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar-free gum containing 20 mg citric acid alone
Study: 11254818
Drug: Oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids (median prednisolone dose 61 g)
Study: 3278494
Drug: Butorphanol, mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol, mean dose 4.8 ± 0.4 mg
Study: 3278494
Drug: Diazepam, mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam, mean dose 12.0 ± 1.0 mg
Study: 28707325
Drug: Remifentanil 1
Normalized name: remifentanil 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 1 μg/kg just before the scalp incision
Study: 23144449
Drug: Increased HCQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased HCQ dose to achieve target [HCQ] ≥1000 ng/ml (group 2)
Study: 23144449
Drug: No daily
Normalized name: Aveeno Daily Moisturizing
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No daily dose change (group 1)
Study: 9178335
Drug: Nortriptyline (50-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline (50-150 ng/ml)
Study: 27075687
Drug: Standard continuous
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard continuous positive airway pressure (CPAP) therapy
Study: 14567091
Drug: Margarine with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Margarine with plant sterol esters (30 g/d with 8 g/100 g of product)
Study: 14567091
Drug: Butter (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butter (30 g/d)
Study: 1390962
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment group (psychological treatment package including relaxation training, electromyogram, and thermal biofeedback)
Study: 16494632
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (delayed treatment)
Study: 3883902
Drug: Topical minoxidil
Normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical minoxidil therapy (1.0 mL applied twice a day)
Study: 3883902
Drug: Topical minoxidil
Normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical minoxidil therapy
Study: 31474546
Drug: Romiplostim 10
Normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Romiplostim 10 μg/kg once weekly
Study: 31474546
Drug: Romiplostim 6
Normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Romiplostim 6 μg/kg once weekly
Study: 31474546
Drug: Romiplostim 3
Normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Romiplostim 3 μg/kg once weekly
Study: 31474546
Drug: Romiplostim 1
Normalized name: ROMIPLOSTIM 125MCG/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romiplostim 1 μg/kg once weekly
Study: 31474546
Drug: Death during
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Death during treatment
Study: 22441892
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg daily for 6 months
Study: 22441892
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg daily for 6 months
Study: 23106243
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg misoprostol
Study: 23106243
Drug: 800 μg
Normalized name: hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 μg misoprostol
Study: 11728269
Drug: Calcium Heparin
Normalized name: HEPARIN CALCIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium Heparin (CH) - 12,500 IU subcutaneous daily for 3 months, followed by 325 mg ASA daily for 3 months
Study: 11728269
Drug: Acetylsalicylic Acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic Acid (ASA) - 325 mg/day for 6 months
Study: 23835185
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with pseudo-intervention of one oral education session
Study: 17875340
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin beta 150 IU/kg three times weekly until 4 weeks after last chemotherapy cycle
Study: 15986591
Drug: CMF as
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF as preoperative second-line chemotherapy
Study: 15986591
Drug: Paclitaxel or
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel or docetaxel as second-line treatment
Study: 12454562
Drug: Rivastigmine (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine (9 mg/day)
Study: 10554542
Drug: Selenium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium treatment for 19 days in addition to a complete in-patient rehabilitation cure based on a behavioural approach
Study: 8974615
Drug: Short-acting GnRH
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting GnRH agonist (effective for 24 hours)
Study: 1718252
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment for classic CNV
Study: 1718252
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment for subfoveal recurrent CNV
Study: 6352267
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg oral)
Study: 8095507
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg three times daily)
Study: 9926571
Drug: Alcohol (100
Normalized name: Polyvinyl Alcohol (100000 Mw)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (100 mg/100 ml dose)
Study: 2838221
Drug: Uniroid ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uniroid ointment
Study: 2838221
Drug: Proctosedyl ointment
DrugBank: Esculin (DB13155)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proctosedyl ointment
Study: 2838221
Drug: Uniroid suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uniroid suppository
Study: 2838221
Drug: Proctosedyl suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proctosedyl suppository
Study: 2838221
Drug: Both ointment
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both ointment and suppository formulations
Study: 2838221
Drug: All four
Normalized name: Jackson's The Original All Fours
Approvals — FDA: no, EMA: no, PMDA: no
Description: All four preparations
Study: 31995570
Drug: Daily lipid‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily lipid‐based micronutrient supplement commencing ≥3 months prior to conception (Arm 1)
Study: 31995570
Drug: Daily lipid‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily lipid‐based micronutrient supplement in the 1st trimester (Arm 2)
Study: 31995570
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no supplement, Arm 3)
Study: 29446523
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with dapagliflozin 10 mg/d plus saxagliptin 5 mg/d plus metformin
Study: 29446523
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy with dapagliflozin or saxagliptin plus metformin
Study: 29446523
Drug: Sequential add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential add-on therapy with dapagliflozin 10 mg/d or saxagliptin 5 mg/d
Study: 29446523
Drug: Concomitant add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant add-on therapy with dapagliflozin 10 mg/d plus saxagliptin 5 mg/d
Study: 28449699
Drug: Full-length shoe-stiffening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-length shoe-stiffening insert(s) plus rehabilitation therapy
Study: 28449699
Drug: Sham shoe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham shoe insert(s) plus rehabilitation therapy
Study: 26134993
Drug: Heparin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin and protamine dosing with Hepcon HMS Plus device
Study: 26134993
Drug: Standard weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard weight and activated clotting time (ACT) based dosing
Study: 22834636
Drug: 15(R/S)-methyl-lipoxin A(4)
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15(R/S)-methyl-lipoxin A(4) cream
Study: 21054484
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 0.5 mL of hypertonic saline
Study: 21054484
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 0.5 mL of isotonic saline
Study: 18298709
Drug: Intravenous lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lorazepam 1 mg
Study: 16376489
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2 (D1, D22, D43); 5FU, continuous infusion (D1‐‐>D5), 750 mg/m2/day cycle 1; 430 mg/m2/day cycles 2 and 3
Study: 16376489
Drug: Cisplatin/5-FU chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin/5-FU chemotherapy (arm B)